RayKnowChina Research Map
Shortlist0

NantongNantong University

Affiliated Hospital of Nantong University

南通大学附属医院

Listed for 21 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Affiliated Hospital of Nantong University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌20 papers led1 open trial led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌22 papers led
  3. Hepatocellular carcinoma肝细胞癌145 papers led
  4. Stomach cancer胃癌107 papers led1 open trial led
  5. Osteosarcoma骨肉瘤9 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤3 papers led
  7. Neuroblastoma神经母细胞瘤10 papers led
  8. Multiple myeloma多发性骨髓瘤16 papers led1 open trial led
  9. Aplastic anaemia再生障碍性贫血2 papers led
  10. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症3 papers led
  11. Haemophilia A血友病 A0 papers led
  12. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  13. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  14. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  15. Amyotrophic lateral sclerosis肌萎缩侧索硬化症5 papers led
  16. Duchenne muscular dystrophy杜氏肌营养不良2 papers led
  17. IgA nephropathyIgA 肾病1 paper led
  18. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  19. Hirschsprung disease先天性巨结肠0 papers led
  20. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
  21. Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Beta thalassaemia, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 20 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
20
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 3320232024: 3320242025: 552025

1 hospital in Nantong for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06389201

    Age 20 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Nantong UniversityNantong

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseInduction / concurrent chemotherapy
Departments in papersENT / head & neck surgery

Over half of these papers are lab or animal studies.

Papers it led20
  1. RFC5 enhances DNA damage response and immune escape via suppressing the cGAS-STING pathway in nasopharyngeal carcinoma.2026Cellular signalling
  2. DDX5 super-enhancer promotes vasculogenic mimicry formation and metastasis in nasopharyngeal carcinoma by enhancing ADAM10 transcription.2025Cell reports. MedicineFree full text
  3. IGF2BP1-HAX-1 positive feedback loop-mediated HAX-1 overexpression blocks autophagic flux and promotes chemoresistance in nasopharyngeal carcinoma.2025Cellular and molecular life sciences : CMLSFree full text
  4. LPAR3 and COL8A1, as matrix stiffness-related biomarkers, promote nasopharyngeal carcinoma metastasis by triggering EMT and angiogenesis.2025Cellular signalling
  5. Hot spots and trends related to chemotherapy in nasopharyngeal carcinoma [2014-2024]: a bibliometric study.2025Chinese clinical oncology
  6. Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5/HMGB1 axis.2025Journal for immunotherapy of cancerFree full text
  7. NAT10 inhibition promotes ac4C-dependent ferroptosis to counteract sorafenib resistance in nasopharyngeal carcinoma.2024Cancer scienceFree full text
  8. Stiffness promotes cell migration, invasion, and invadopodia in nasopharyngeal carcinoma by regulating the WT-CTTN level.2024Cancer science
  9. FGF19 promotes nasopharyngeal carcinoma progression by inducing angiogenesis via inhibiting TRIM21-mediated ANXA2 ubiquitination.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  10. RCN2 promotes Nasopharyngeal carcinoma progression by curbing Calcium flow and Mitochondrial apoptosis.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  11. Effects of abnormal expression of CD73 on malignant phenotype of nasopharyngeal carcinoma.2023Journal of molecular histology
  12. Hypoxic nasopharyngeal carcinoma-derived exosomal miR-455 increases vascular permeability by targeting ZO-1 to promote metastasis.2023Molecular carcinogenesis
  13. AMPK-mTOR-Mediated Activation of Autophagy Promotes Formation of Dormant Polyploid Giant Cancer Cells.2022Cancer researchFree full text
  14. Extracellular vesicles rich in HAX1 promote angiogenesis by modulating ITGB6 translation.2022Journal of extracellular vesiclesFree full text
  15. Tumor-derived exosomal lincRNA ROR promotes angiogenesis in nasopharyngeal carcinoma.2022Molecular and cellular probes
  16. MIR106A-5p upregulation suppresses autophagy and accelerates malignant phenotype in nasopharyngeal carcinoma.2021AutophagyFree full text
  17. Exosomal ERp44 derived from ER-stressed cells strengthens cisplatin resistance of nasopharyngeal carcinoma.2021BMC cancerFree full text
  18. HIF-1α downregulation of miR-433-3p in adipocyte-derived exosomes contributes to NPC progression via targeting SCD1.2021Cancer scienceFree full text
  19. Nuclear exosome HMGB3 secreted by nasopharyngeal carcinoma cells promotes tumour metastasis by inducing angiogenesis.2021Cell death & diseaseFree full text
  20. ER resident protein 44 promotes malignant phenotype in nasopharyngeal carcinoma through the interaction with ATP citrate lyase.2021Journal of translational medicineFree full text
Chinese-language papers (not in the count)2
  1. [An analysis of long-term survival trends for nasopharyngeal carcinoma in Qidong, Jiangsu].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Autophagy promotes recurrence of nasopharyngeal carcinoma via inducing the formation of dormant polyploid giant cancer cells].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
All its trials on ClinicalTrials.gov, any status3
  1. Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC PatientsRecruitingNCT06389201Lead sponsorN/AStart 2024-08
  2. Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC PatientsStatus unknownNCT06442709Lead sponsorN/AStart 2021-08
  3. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
More papers found outside PubMed (not counted)4
  1. WITHDRAWN: 1440TiP Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine(GX) versus tislelizumab plus gemcitabine/cisplatin(GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multic2025Annals of Oncologyretraction
  2. Data from AMPK–mTOR–Mediated Activation of Autophagy Promotes Formation of Dormant Polyploid Giant Cancer Cells2023Venue not listedother
  3. MicroRNA-433 Inhibits Migration and Proliferation of Nasopharyngeal Carcinoma by Targeting Hypoxia- Induced Factor 1α2022Research Squarepreprint
  4. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 22 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
22
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 7720222023: 3320232024: 4420242025: 662025

2 hospitals in Nantong for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05443841

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsImaging & AIImmunotherapy
Departments in papersRadiology / nuclear medicineMedical oncologyPathology / laboratory medicineRadiation oncology
Papers it led22
  1. Preoperative esophageal cancer staging assessment based on intravoxel incoherent motion and apparent diffusion coefficient: a comparative study of maximum-diameter slice region of interest and whole volume of interest analysis.2025BMC medical imagingFree full text
  2. CAFs-derived Exosomal miR-889-3p Might Repress M1 Macrophage Polarization to Boost ESCC Development by Regulating STAT1.2025Cell biochemistry and biophysics
  3. SUMO-Specific Peptidase 5 Promotes Oesophageal Squamous Cell Carcinoma Growth through the NF-κB-SLC1A3 Axis.2025Frontiers in bioscience (Landmark edition)
  4. Multi-cohort validation based on coagulation-related genes for predicting prognosis of esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  5. Correlation of immune cell subsets in the tumor microenvironment and peripheral blood with immunotherapy response in esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  6. TAK1-mediated phosphorylation of PLCE1 represses PIP2 hydrolysis to impede esophageal squamous cancer metastasis.2025eLifeFree full text
  7. Preoperative Prediction of Perineural Invasion in Oesophageal Squamous Cell Carcinoma Based on CT Radiomics Nomogram: A Multicenter Study.2024Academic radiology
  8. Clinicopathological, metastatic and prognostic features of stage IV esophageal adenocarcinoma versus squamous cell carcinoma: a SEER database analysis.2024Chinese clinical oncology
  9. TAPI-1 Exhibits Anti-tumor Efficacy in Human Esophageal Squamous Cell Carcinoma Cells via Suppression of NF-κB Signaling Pathway.2024Digestive diseases and sciencesFree full text
  10. SPINK5 inhibits esophageal squamous cell carcinoma metastasis via immune activity.2024The journal of gene medicine
  11. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.2023Cancer medicineRCTFree full text
  12. High Expression Level of BRD4 Is Associated with a Poor Prognosis and Immune Infiltration in Esophageal Squamous Cell Carcinoma.2023Digestive diseases and sciencesFree full text
  13. AKAP12 inhibits esophageal squamous carcinoma cell proliferation, migration, and cell cycle via the PI3K/AKT signaling pathway.2023Molecular and cellular probes
  14. Computed Tomography-Based Radiomics Nomogram for Predicting the Postoperative Prognosis of Esophageal Squamous Cell Carcinoma: A Multicenter Study.2022Academic radiologyRCT
  15. Low expression of PRDM5 predicts poor prognosis of esophageal squamous cell carcinoma.2022BMC cancerFree full text
  16. HLA complex P5 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma.2022BioengineeredFree full text
  17. New Metabolic Alterations and A Predictive Marker Pipecolic Acid in Sera for Esophageal Squamous Cell Carcinoma.2022Genomics, proteomics & bioinformaticsFree full text
  18. RASSF10 exhibits tumor‑suppressing potential involving tumor proliferation, metastasis and epithelial‑mesenchymal transition in esophageal squamous cell carcinoma.2022Oncology reportsFree full text
  19. Computed tomography-based radiomics analysis to predict lymphovascular invasion in esophageal squamous cell carcinoma.2022The British journal of radiologyFree full text
  20. Effect of different surgical approaches on the prognosis of patients with postoperative radiotherapy for stage IIB-IVA esophageal squamous cancer.2022World journal of surgical oncologyFree full text
  21. Esophageal Carcinosarcoma: Analysis of Clinical Features and Prognosis of 24 Cases and a Literature Review.2021Cancer control : journal of the Moffitt Cancer CenterFree full text
  22. Pyk2 level is a novel prognostic marker for patients with esophageal squamous cell carcinoma after radical surgery.2021Virchows Archiv : an international journal of pathology
All its trials on ClinicalTrials.gov, any status2
  1. PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCCStatus unknownNCT06186609Lead sponsorPhase 2Start 2023-07
  2. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)RecruitingNCT05443841Study siteStart 2022-07
More papers found outside PubMed (not counted)3
  1. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  2. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figsharedataset
  3. Radical Resection of T3N2M0 Esophageal Cancer Under Bilateral Thoracoscopy: A Case Report2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 145 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.0%.

Papers led
145
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 151520212022: 181820222023: 313120232024: 454520242025: 32322025

2 hospitals in Nantong for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiology / nuclear medicineGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led145
  1. PD-1+/CXCR6+CD8+T lymphocytes promote MASLD malignant progression through inflammatory and immune dysregulation.2026International immunopharmacology
  2. Prediction of PD-1 Expression and Outcomes of Combined Therapy in Hepatocellular Carcinoma: an MRI-Based Radiomics Approach.2026Journal of imaging informatics in medicineFree full text
  3. Outcomes of laparoscopic versus open liver resection in patients with large or huge HCC: a multicenter study.2026Surgical endoscopy
  4. A multicenter case-controlled study on laparoscopic hepatectomy versus open liver resection as first-line therapy for solitary hepatocellular carcinoma in elderly patients.2026Surgical endoscopy
  5. tRNA-Derived Small RNA Accelerates Tumorigenesis through Crosstalk with Tumor-Associated Macrophages, and Downregulation with Cell Membrane-Modified Polymer Nanoparticles Enables Treatment Response.2025ACS applied materials & interfacesFree full text
  6. Enhancing Chemotherapy Efficacy via an Autologous Erythrocyte-Anchoring Strategy with a Closed-System Drug-Transfer Device.2025ACS biomaterials science & engineering
  7. Gadoxetic Acid-Enhanced MRI-Based Radiomic Models for Preoperative Risk Prediction and Prognostic Assessment of Proliferative Hepatocellular Carcinoma.2025Academic radiology
  8. MRI-Based Models Using Habitat Imaging for Predicting Distinct Vascular Patterns in Hepatocellular Carcinoma.2025Academic radiology
  9. G protein-coupled receptor GPR182 negatively regulates sprouting angiogenesis via modulating CXCL12-CXCR4 axis signaling.2025AngiogenesisFree full text
  10. Evaluation of serum hsa_tsr014055 as a potential biomarker for diagnosis and prognosis of hepatocellular carcinoma.2025Annals of medicineFree full text
  11. Alterations of Krüppel-like Factor Signaling and Potential Targeted Therapy for Hepatocellular Carcinoma.2025Anti-cancer agents in medicinal chemistry
  12. Decoding the role of nucleic acid binding protein 2 in lipid dysregulation and hepatocellular carcinoma progression through LKB1-mediated mitochondrial dysfunction.2025Cellular signalling
  13. tRF-23-R9J89O9N9:A novel liquid biopsy marker for diagnosis of hepatocellular carcinoma.2025Clinica chimica acta; international journal of clinical chemistry
  14. Development and evaluation of a nutritional risk prediction model for patients with hepatocellular carcinoma undergoing transarterial chemoembolisation.2025Clinical and experimental medicineFree full text
  15. Improving Outcomes in Hepatocellular Carcinoma through Integration of Machine Learning: Development of a Tumor-Associated Macrophage Signature.2025Digestive diseases (Basel, Switzerland)
  16. cPDS Promotes Cell Apoptosis by Reducing the Translational Efficiency of BIRC3 mRNA in HCC.2025Digestive diseases and sciencesFree full text
  17. Significance of anatomical resection and wide surgical margin for HCC patients with MVI undergoing laparoscopic hepatectomy: A multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  18. ALG3 as a prognostic biomarker and mediator of PD-1 blockade resistance in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  19. Understanding the relationship between cuproptosis and the development of hepatocellular carcinoma: implications for targeted therapies.2025Frontiers in immunologyFree full text
  20. Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  21. Exploring the clinical application and biological function of novel tsRNA tsRNA-Asp-5-0002 in hepatocellular carcinoma.2025Gene
  22. KGF secreted from HSCs activates PAK4/BMI1, promotes HCC stemness through PI3K/AKT pathway.2025IUBMB life
  23. Monoterpene Sabinene Suppresses Hepatocarcinoma by Regulating the AKT/mTOR and Bcl-2/Bax Signaling Pathways: An In Vivo and In Vitro Analysis.2025Journal of biochemical and molecular toxicology
  24. tRF-34-P4R8YP9LON4VHM Promotes Hepatocellular Carcinoma Progression and Tumour Cell-Induced Angiogenesis via the MEK/ERK Pathway.2025Journal of cellular and molecular medicineFree full text
  25. Reduction of alternative polarization of macrophages by short-term activated hepatic stellate cell-derived small extracellular vesicles.2025Journal of experimental & clinical cancer research : CRFree full text
  26. NUSAP1 Promotes Immunity and Apoptosis by the SHCBP1/JAK2/STAT3 Phosphorylation Pathway to Induce Dendritic Cell Generation in Hepatocellular Carcinoma.2025Journal of immunotherapy (Hagerstown, Md. : 1997)Free full text
  27. Diagnostic Model for Proliferative HCC Using LI-RADS: Assessing Therapeutic Outcomes in Hepatectomy and TKI-ICI Combination.2025Journal of magnetic resonance imaging : JMRI
  28. Tregs With High CD29 Expression Promote Cell Adhesion and Contribute to the Malignant Transformation of MASLD.2025Liver international : official journal of the International Association for the Study of the LiverFree full text
  29. TMEM115 as an Oncogenic and Immunological Biomarker in Hepatocellular Carcinoma.2025Liver international : official journal of the International Association for the Study of the Liver
  30. Dynamic ubiquitination networks in liver cancer: decoding E3 ligases and deubiquitinases as gatekeepers of therapeutic resistance.2025Medical oncology (Northwood, London, England)
  31. TSPAN15 enhances EMT-mediated metastasis of HCC by promoting autophagy through BTRC-mediated PDCD4 degradation.2025Molecular immunology
  32. COPB2 promotes hepatocellular carcinoma progression through regulation of YAP1 nuclear translocation.2025Oncology researchFree full text
  33. Mitochondrial proteins: Potential pathophysiological mechanisms of malignant progression in HCC.2025PloS oneFree full text
  34. Constructing a prognostic signature of tumor-associated B lymphocytes in hepatocellular carcinoma via machine learning integration.2025Scientific reportsFree full text
  35. mRNA decapping enzyme2 DCP2 expression correlates with progression and prognosis of hepatocellular carcinoma.2025Scientific reportsFree full text
  36. Impact of postoperative morbidity on the prognosis of patients with hepatocellular carcinoma after laparoscopic liver resection: a multicenter observational study.2025Scientific reportsFree full text
  37. Nodule-in-nodule architecture of hepatocellular carcinomas: enhancement patterns in the hepatobiliary phase and pathological features.2024Abdominal radiology (New York)
  38. Self-Produced O2 CNs-Based Nanocarriers of DNA Hydrophobization Strategy Triggers Photodynamic and Mitochondrial-Derived Ferroptosis for Hepatocellular Carcinoma Combined Treatment.2024Advanced healthcare materials
  39. Comprehensive characterization of Fidgetin on tumor immune microenvironment evaluation and immunotherapy in human hepatocellular carcinoma.2024AgingFree full text
  40. Grading severity of MVI impacts long-term outcomes after laparoscopic liver resection for early-stage hepatocellular carcinoma: A multicenter study.2024American journal of surgery
  41. USP14 exhibits high expression levels in hepatocellular carcinoma and plays a crucial role in promoting the growth of liver cancer cells through the HK2/AKT/P62 axis.2024BMC cancerFree full text
  42. Hsa_circ_0005397 promotes hepatocellular carcinoma progression through EIF4A3.2024BMC cancerFree full text
  43. DNA tetrahedral scaffold-corbelled self-feedback circuit for dual-mode ratiometric biosensing with Ru@COF-LZU1 accelerator.2024Biosensors & bioelectronics
  44. Hsa_circ_0079875 functions as a competitive endogenous RNA to promote hepatocellular carcinoma progression.2024Cell cycle (Georgetown, Tex.)Free full text
  45. Ubiquitin-specific protease 1 facilitates hepatocellular carcinoma progression by modulating mitochondrial fission and metabolic reprogramming via cyclin-dependent kinase 5 stabilization.2024Cell death and differentiationFree full text
  46. Lysosome-Related Genes and RNF19B as Prognostic Markers for Survival and Immunotherapy Efficacy in Hepatocellular Carcinoma.2024Clinical and translational gastroenterologyFree full text
  47. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8+ T-cell infiltration in hepatocellular carcinoma.2024Clinical and translational medicineFree full text
  48. Exploration of Key Genes Combining with Immune Infiltration Level andTumor Mutational Burden in Hepatocellular Carcinoma.2024Combinatorial chemistry & high throughput screening
  49. SIAH2-Mediated Degradation of ACSL4 Inhibits the Anti-Tumor Activity of CD8+ T Cells in Hepatocellular Carcinoma.2024Critical reviews in eukaryotic gene expression
  50. Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK Signaling Pathway.2024Current cancer drug targets
  51. Hypoxia-induced TRPM7 promotes glycolytic metabolism and progression in hepatocellular carcinoma.2024European journal of pharmacology
  52. Letter to the editor "A preoperative model for predicting early recurrence in patients undergoing resection for single hepatocellular carcinoma".2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  53. Integrating single cell analysis and machine learning methods reveals stem cell-related gene S100A10 as an important target for prediction of liver cancer diagnosis and immunotherapy.2024Frontiers in immunologyFree full text
  54. Targeting liver cancer stem cells: the prognostic significance of MRPL17 in immunotherapy response.2024Frontiers in immunologyFree full text
  55. Activated hepatic stellate cell-derived small extracellular vesicles facilitate M2 macrophage polarization and hepatoma progression via miR-27a-3p.2024Frontiers in immunologyFree full text
  56. The mechanism of PDE7B inhibiting the development of hepatocellular carcinoma through oxidative stress.2024Frontiers in immunologyFree full text
  57. Ubiquitination-specific protease 7 enhances stemness of hepatocellular carcinoma by stabilizing basic transcription factor 3.2024Functional & integrative genomics
  58. Comprehensive Analysis of the Mechanism of Anoikis in Hepatocellular Carcinoma.2024Genetics researchFree full text
  59. Is laparoscopic liver resection more suitable for diabetic patients with hepatocellular carcinoma? The debate continues.2024Hepatology international
  60. Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed.2024Hepatology international
  61. Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues.2024Hepatology international
  62. CircGNAO1 suppresses hepatocellular carcinoma progression and metastasis via sponging miR-182-5p and regulating FOXO1 expression.2024International immunopharmacology
  63. Meta-analysis of cryoablation versus radiofrequency ablation in the treatment of malignant liver tumors.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  64. Featured lncRNA-based signature for discriminating prognosis and progression of hepatocellular carcinoma.2024Journal of applied genetics
  65. Body mass index is a risk factor for postoperative morbidity after laparoscopic hepatectomy of hepatocellular carcinoma: a multicenter retrospective study.2024Journal of cancer research and clinical oncologyFree full text
  66. Downregulation of GLYAT correlates with tumour progression and poor prognosis in hepatocellular carcinoma.2024Journal of cellular and molecular medicineFree full text
  67. Preoperative Gadoxetic Acid-Enhanced MRI Features for Evaluation of Vessels Encapsulating Tumor Clusters and Microvascular Invasion in Hepatocellular Carcinoma: Creating Nomograms for Risk Assessment.2024Journal of magnetic resonance imaging : JMRI
  68. ACYP2 functions as an innovative nano-therapeutic target to impede the progression of hepatocellular carcinoma by inhibiting the activity of TERT and the KCNN4/ERK pathway.2024Journal of nanobiotechnologyFree full text
  69. Lymphocyte Function in Tertiary Lymphoid Structures Predicts Hepatocellular Carcinoma Outcome.2024Laboratory investigation; a journal of technical methods and pathology
  70. Effect of Noise Management in Interventional Radiology Suites on Patients Undergoing Transarterial Chemoembolization: A Retrospective Study.2024Noise & healthFree full text
  71. HOMER3 promotes liver hepatocellular carcinoma cancer progression by -upregulating EZH2 and mediating miR-361/GPNMB axis.2024Pathology, research and practice
  72. Upregulation of LHPP by saRNA inhibited hepatocellular cancer cell proliferation and xenograft tumor growth.2024PloS oneFree full text
  73. Identification of serum tsRNA-Thr-5-0015 and combined with AFP and PIVKA-II as novel biomarkers for hepatocellular carcinoma.2024Scientific reportsFree full text
  74. DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C.2024Scientific reportsFree full text
  75. Multi-omics analysis of macrophage-associated receptor and ligand reveals a strong prognostic signature and subtypes in hepatocellular carcinoma.2024Scientific reportsFree full text
  76. CircGPC3 promotes hepatocellular carcinoma progression and metastasis by sponging miR-578 and regulating RAB7A/PSME3 expression.2024Scientific reportsFree full text
  77. Letter to the Editor on: "Risk factors, patterns, and outcome predictors of late recurrence in patients with hepatocellular carcinoma after curative resection: A large cohort study with long-term follow-up results".2024Surgery
  78. Commentary on "Comparison between laparoscopic liver resection and open liver resection in patients with hepatocellular carcinoma with portal vein tumor thrombosis".2024Surgical endoscopy
  79. Probing Dual Covalent Irreversible Inhibition of EGFR/FGFR4 by Electrophilic-Based Natural Compounds to Overcome Resistance and Enhance Combination Therapeutic Potentials and Management of Hepatocellular Carcinoma (HCC).2024The protein journal
  80. MRPL21 promotes HCC proliferation through TP53 mutation-induced apoptotic resistance.2024Tissue & cell
  81. Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation.2024World journal of gastroenterologyFree full text
  82. Computed tomography texture analysis combined with preoperative clinical factors serve as a predictor of early efficacy of transcatheter arterial chemoembolization in hepatocellular carcinoma.2023Abdominal radiology (New York)
  83. Prediction for Aggressiveness and Postoperative Recurrence of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced Magnetic Resonance Imaging.2023Academic radiology
  84. circSLCO1B7 suppresses the malignant progression of hepatocellular carcinoma via the miR-556-3p/DAB2IP axis.2023AgingFree full text
  85. Expression and function of myelin expression factor 2 in hepatocellular carcinoma.2023BMC gastroenterologyFree full text
  86. M7G methylated core genes (METTL1 and WDR4) and associated RNA risk signatures are associated with prognosis and immune escape in HCC.2023BMC medical genomicsFree full text
  87. Dehydrocostus Lactone Reduced Malignancy of HepG2 Human Hepatocellular Carcinoma Cells via Down-Regulation of the PI3K/AKT Signaling Pathway.2023Bulletin of experimental biology and medicine
  88. Sestrin2: multifaceted functions, molecular basis, and its implications in liver diseases.2023Cell death & diseaseFree full text
  89. Identification of anoikis related subtypes and construction of prognostic model in hepatocellular carcinoma.2023Cellular and molecular biology (Noisy-le-Grand, France)
  90. Identification of acetyl-CoA carboxylase alpha as a prognostic and targeted candidate for hepatocellular carcinoma.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  91. KRTCAP2 as an immunological and prognostic biomarker of hepatocellular carcinoma.2023Colloids and surfaces. B, Biointerfaces
  92. RBM12 regulates the progression of hepatocellular cancer via miR-497-5p/CPNE1 Axis.2023Environmental research
  93. Overexpression of TMEM79 combined with SMG5 is related to prognosis, tumor immune infiltration and drug sensitivity in hepatocellular carcinoma.2023European journal of medical researchFree full text
  94. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.2023European journal of medical researchFree full text
  95. Integrated investigation of the clinical implications and targeted landscape for RNA methylation modifications in hepatocellular carcinoma.2023European journal of medical researchFree full text
  96. A commentary on "A new prognostic model predicting hepatocellular carcinoma early recurrence in patients with microvascular invasion who received postoperative adjuvant transcatheter arterial chemoembolization".2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  97. Insights into the Role of Oxidative Stress in Hepatocellular Carcinoma Development.2023Frontiers in bioscience (Landmark edition)
  98. PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  99. Oncogenic Wnt3a is a promising sensitive biomarker for monitoring hepatocarcinogenesis.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  100. Cellular senescence in liver diseases: From mechanisms to therapies.2023International immunopharmacology
  101. Minichromosome maintenance protein family member 6 mediates hepatocellular carcinoma progression by recruiting UBE3A to induce P53 ubiquitination.2023International journal of biological macromolecules
  102. A commentary on 'Significance of anatomical resection and resection margin status in patients with HBV-related hepatocellular carcinoma and microvascular invasion: a multicenter propensity score-matched study'.2023International journal of surgery (London, England)Free full text
  103. Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.2023Journal of advanced researchFree full text
  104. Prognostic related gene index for predicting survival and immunotherapeutic effect of hepatocellular carcinoma.2023MedicineFree full text
  105. Radiomics Based on Contrast-Enhanced CT for Recognizing c-Met-Positive Hepatocellular Carcinoma: a Noninvasive Approach to Predict the Outcome of Sorafenib Resistance.2023Molecular imaging and biology
  106. Tumor-derived exosomes promote macrophages M2 polarization through miR-1-3p and regulate the progression of liver cancer.2023Molecular immunology
  107. RNA-binding motif 4 promotes angiogenesis in HCC by selectively activating VEGF-A expression.2023Pharmacological research
  108. Ginsenoside Rh2: A shining and potential natural product in the treatment of human nonmalignant and malignant diseases in the near future.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  109. Construction of a ceRNA regulatory network to explore potential pathogenesis mechanisms involved in human hepatocellular carcinoma.2023Scientific reportsFree full text
  110. DLAT is a promising prognostic marker and therapeutic target for hepatocellular carcinoma: a comprehensive study based on public databases.2023Scientific reportsFree full text
  111. A model incorporating histopathology and preoperative gadoxetic acid-enhanced MRI to predict early recurrence of hepatocellular carcinoma without microvascular invasion after curative hepatectomy.2023The British journal of radiologyFree full text
  112. Function and biomedical implications of exosomal microRNAs delivered by parenchymal and nonparenchymal cells in hepatocellular carcinoma.2023World journal of gastroenterologyFree full text
  113. Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma.2022AgingFree full text
  114. Long-term oncological prognosis after curative-intent liver resection for hepatocellular carcinoma in the young versus the elderly: multicentre propensity score-matching study.2022BJS openFree full text
  115. Nuclear respiratory factor 1 promotes the growth of liver hepatocellular carcinoma cells via E2F1 transcriptional activation.2022BMC gastroenterologyFree full text
  116. Using pre-operative radiomics to predict microvascular invasion of hepatocellular carcinoma based on Gd-EOB-DTPA enhanced MRI.2022BMC medical imagingRCTFree full text
  117. Development and Validation of a Novel Circadian Rhythm-Related Signature to Predict the Prognosis of the Patients with Hepatocellular Carcinoma.2022BioMed research internationalFree full text
  118. Circular RNA hsa_circ_0051040 Promotes Hepatocellular Carcinoma Progression by Sponging miR-569 and Regulating ITGAV Expression.2022CellsFree full text
  119. Screening and Validation of a Carvacrol-Targeting Viability-Regulating Protein, SLC6A3, in Liver Hepatocellular Carcinoma.2022Disease markersFree full text
  120. Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  121. Flap endonuclease 1 Facilitated Hepatocellular Carcinoma Progression by Enhancing USP7/MDM2-mediated P53 Inactivation.2022International journal of biological sciencesFree full text
  122. Involvement of microRNAs and their potential diagnostic, therapeutic, and prognostic role in hepatocellular carcinoma.2022Journal of clinical laboratory analysisFree full text
  123. Hsa_circ_0000098 is a novel therapeutic target that promotes hepatocellular carcinoma development and resistance to doxorubicin.2022Journal of experimental & clinical cancer research : CRFree full text
  124. A Web-Based Prediction Model for Estimating the Probability of Post-hepatectomy Major Complications in Patients with Hepatocellular Carcinoma: A Multicenter Study from a Hepatitis B Virus-Endemic Area.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  125. Prognostic Significance of Preoperative Integrated Liver Inflammatory Score in Patients with Hepatocellular Carcinoma.2022Medical science monitor : international medical journal of experimental and clinical researchFree full text
  126. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.2022Molecular biology reports
  127. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.2022Molecular immunology
  128. Clinicopathological features and genomic profiles of hepatoid adenocarcinoma of the lung: Report of four cases.2022Pathology, research and practice
  129. Associations of MALAT1 and its functional single nucleotide polymorphisms with cancer.2022Pathology, research and practice
  130. Hypoxia-induced RNASEH2A limits activation of cGAS-STING signaling in HCC and predicts poor prognosis.2022Tumori
  131. Elevated serum alpha-fetoprotein levels are associated with poor prognosis of hepatocellular carcinoma after surgical resection: A systematic review and meta-analysis.2021Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  132. RBM23 Drives Hepatocellular Carcinoma by Activating NF-κB Signaling Pathway.2021BioMed research internationalFree full text
  133. LncRNA DHRS4-AS1 ameliorates hepatocellular carcinoma by suppressing proliferation and promoting apoptosis via miR-522-3p/SOCS5 axis.2021BioengineeredFree full text
  134. Long non-coding RNA SNHG22 facilitates hepatocellular carcinoma tumorigenesis and angiogenesis via DNA methylation of microRNA miR-16-5p.2021BioengineeredFree full text
  135. LINC00839/miR-144-3p/WTAP (WT1 Associated protein) axis is involved in regulating hepatocellular carcinoma progression.2021BioengineeredFree full text
  136. H2A.Z acetylation by lincZNF337-AS1 via KAT5 implicated in the transcriptional misregulation in cancer signaling pathway in hepatocellular carcinoma.2021Cell death & diseaseFree full text
  137. The Emerging Roles of Exosomes in the Chemoresistance of Hepatocellular Carcinoma.2021Current medicinal chemistry
  138. The role of ceRNA-mediated diagnosis and therapy in hepatocellular carcinoma.2021HereditasFree full text
  139. CLTRN, Regulated by NRF1/RAN/DLD Protein Complex, Enhances Radiation Sensitivity of Hepatocellular Carcinoma Cells Through Ferroptosis Pathway.2021International journal of radiation oncology, biology, physics
  140. Predictive value of and relationship between the gamma-glutamyl transpeptidase to lymphocyte ratio and CT features in hepatocellular carcinoma patients with postoperative adjuvant TACE.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  141. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.2021Journal of cancer research and therapeutics
  142. DNMT1-induced miR-378a-3p silencing promotes angiogenesis via the NF-κB signaling pathway by targeting TRAF1 in hepatocellular carcinoma.2021Journal of experimental & clinical cancer research : CRFree full text
  143. A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular Carcinoma.2021Journal of natural products
  144. MicroRNA-92b-3p promotes the progression of liver fibrosis by targeting CREB3L2 through the JAK/STAT signaling pathway.2021Pathology, research and practice
  145. Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)6
  1. [CENPI promotes the migration of liver cancer cells and the epithelial-mesenchymal transition process by activating the RAS/MEK/ERK signaling axis].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Hepatobiliary phase image manifestation classification and pathological features of nodules in nodules accompanied by hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Overexpression of tuftelin and KLF-5 and its clinicopathological features in hepatitis B virus-related hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  4. [Alteration of Wnt3a overexpression and its early monitoring value during hepatocellular carcinogenesis].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  5. [Value of abnormal expression of Krüppel-like zinc-finger protein transcription factor 5 in the diagnosis and prognosis of liver cancer].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  6. [Expression of tuftelin protein and its clinical value in HBV-related liver cancer tissues].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  2. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  3. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 107 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.1%.

Papers led
107
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 161620212022: 161620222023: 171720232024: 202020242025: 34342025

1 hospital in Nantong for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    Screening of Small Non-coding RNAs as an Auxiliary Diagnostic Biomarker for Gastric Cancer
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06776835

    Age 18 years to 85 years (registered criteria)

    Led by Affiliated Hospital of Nantong UniversityNantong

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseSurgeryEarly detection & endoscopy
Departments in papersPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led107
  1. Overexpression of miR-195-5p Suppresses Gastric Cancer Progression by Regulating LAMP2-Mediated Autophagy.2026Biochemical geneticsFree full text
  2. [Expression of Concern] Effects of cullin 4B on the proliferation and invasion of human gastric cancer cells.2026Molecular medicine reportsFree full text
  3. Telomere-protecting protein 1 promotes gastric cancer cell metastasis via enhancing endoplasmic reticulum stress.2026The Journal of biological chemistryFree full text
  4. Tumor microenvironment-driven ST6Gal-Ⅰ activation promotes aggressiveness in gastric signet-ring cell carcinoma via ITGβ1/FAK/Paxillin signaling.2026Tissue & cell
  5. VSIG2 hinders gastric cancer progression by suppressing ANXA2-mediated NF-κB pathway activation.2025Acta biochimica et biophysica SinicaFree full text
  6. Development and validation of a diagnostic and screening method for gastric cancer by combining new gastric cancer screening score and serum biomarkers: a prospective study.2025BMC cancerFree full text
  7. Granzyme B Promotes Proliferation, Migration and EMT Process in Gastric Cancer.2025Biochemical genetics
  8. Enhanced IL36RN Expression and Its Association With Immune Microenvironment Predicts Poor Prognosis in Gastric Cancer.2025Cancer medicineFree full text
  9. The MIR181A2HG/miR-5680/VCAN-CD44 Axis Regulates Gastric Cancer Lymph Node Metastasis by Promoting M2 Macrophage Polarization.2025Cancer medicineFree full text
  10. A novel serum biomarker Enhancer RNA RASSF8-AS1 promotes the progression of gastric cancer.2025Carcinogenesis
  11. Systematic assessment of serum i-tRF-AsnGTT in gastric cancer: a potential clinical biomarker.2025Carcinogenesis
  12. NLRP12 decreases TRIM25-mediated HK2 degradation to promote glycolysis and H3K18la in gastric cancer.2025Cell death & diseaseFree full text
  13. The cancer-testis lncRNA LINC01940 promotes gastric cancer malignant progression and chemoresistance by enhancing ribosome biogenesis via TAF15-mediated NOL11 SUMOylation.2025Cellular & molecular biology lettersFree full text
  14. SPTSSA facilitates gastric cancer progression with modulating PD-L1 in immunomicroenvironment through Wnt/β-catenin pathway.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  15. PRDX2 promotes gastric cancer progression by forming a feedback loop with PKM2/STAT3 axis.2025Cellular signalling
  16. Serum tRF-18-HR05X6D2 may serve as a promising potential diagnostic biomarker for gastric cancer.2025Clinical and experimental medicineFree full text
  17. Serum STARD4-AS1 as a Novel Marker for Gastric Cancer Diagnosis and Promotes Gastric Cancer Progression.2025Clinical and translational gastroenterologyFree full text
  18. Exploring the diagnostic potential of serum 5'tRF-Lys as a novel gastric cancer biomarker.2025Clinical biochemistry
  19. Development and validation of a preoperative CT-based risk score integrating morphological and body composition parameters to predict recurrence-free survival in gastric cancer patients following curative surgery.2025European journal of radiology
  20. Baseline and early changes in CT body composition can predict recurrence-free survival after radical gastrectomy: A sex-specific study.2025European journal of radiology
  21. Cost-effectiveness analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer.2025Frontiers in public healthFree full text
  22. Elucidating the Role of THPO and Related Molecular Markers in Lymph Node Metastasis and Prognosis of Gastric Cancer: Insights From TCGA Data Analysis.2025Genetics researchFree full text
  23. The role of CD101 and Tim3 in the immune microenvironment of gastric cancer and their potential as prognostic biomarkers.2025International immunopharmacology
  24. Prp19/CDC5L promotes gastric cancer via activation of the MAPK pathway-mediated homologous recombination.2025International journal of biological sciencesFree full text
  25. CSF2RA promotes gastric cancer progression through activation of the JAK2/STAT3 signaling pathway.2025Journal of molecular histology
  26. miR-378d suppresses gastric cancer metastasis by targeting METTL4 to inhibit epithelial-mesenchymal transition.2025Journal of molecular histology
  27. MFAP2 promotes the malignant progression of gastric cancer via activating the PI3K/AKT signaling pathway.2025Journal of receptor and signal transduction research
  28. HECW1-Mediated Ubiquitination of HIPK2 Drives Metastasis in Gastric Cancer Through the AKT Signaling Pathway.2025Laboratory investigation; a journal of technical methods and pathology
  29. Endoscopic diagnosis of gastric carcinoma of fundic gland type: A case report.2025MedicineFree full text
  30. NLRP3 inflammasome expression affects immune cell infiltration and clinical prognosis in Helicobacter pylori infection‑associated gastric cancer.2025Molecular medicine reportsFree full text
  31. Nociceptive neurons promote gastric tumour progression via a CGRP-RAMP1 axis.2025NatureFree full text
  32. Identification and potential mechanism of a novel gastric cancer suppressor tRF-24-6VR8K09LE9.2025Naunyn-Schmiedeberg's archives of pharmacology
  33. lncRNA SNHG4 enhanced gastric cancer progression by modulating miR-409-3p/CREB1 axis.2025Oncology researchFree full text
  34. NKAIN1 expression relates to the immune evasion and prognosis of gastric cancer.2025Scientific reportsFree full text
  35. MAGEA11 promotes GC proliferation, migration, and invasion through activation of E2F1 transcriptional activity.2025Scientific reportsFree full text
  36. Prognostic molecular subtype reveals the heterogeneity of tumor immune microenvironment in gastric cancer.2025Scientific reportsFree full text
  37. Mechanism and role of H. pylori CagA-induced NLRP3 inflammasome in gastric cancer immune cell infiltration.2025Scientific reportsFree full text
  38. Mapping the landscape of ovarian metastases of gastric cancer: insights, trends, and emerging perspectives.2025World journal of surgical oncologyFree full text
  39. Machine learning for identifying tumor stemness genes and developing prognostic model in gastric cancer.2024AgingFree full text
  40. Survival impact of gastrectomy and chemotherapy on gastric signet ring-cell carcinoma with different metastatic lesions: A population-based study.2024Asian journal of surgery
  41. Potential clinical significance of ALDH3B1 in auxiliary diagnosis of gastric cancer.2024Biomarkers in medicine
  42. Diagnostic and prognostic value of the gasdermins in gastric cancer.2024Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicasFree full text
  43. Human circular RNA hsa_circ_0000231 clinical diagnostic effectiveness as a new tumor marker in gastric cancer.2024Cancer reports (Hoboken, N.J.)Free full text
  44. Circular RNA circWNK1 inhibits the progression of gastric cancer via regulating the miR-21-3p/SMAD7 axis.2024Cancer science
  45. RUNX1, FUS, and ELAVL1-induced circPTPN22 promote gastric cancer cell proliferation, migration, and invasion through miR-6788-5p/PAK1 axis-mediated autophagy.2024Cellular & molecular biology lettersFree full text
  46. Clinical value assessment for serum hsa_tsr013526 in the diagnosis of gastric carcinoma.2024Environmental toxicology
  47. Dysregulated transfer RNA-derived small RNAs as potential gastric cancer biomarkers.2024Experimental biology and medicine (Maywood, N.J.)Free full text
  48. PCDHGA10 as a potential prognostic biomarker and correlated with immune infiltration in gastric cancer.2024Frontiers in immunologyFree full text
  49. Identification of an autophagy- and macropinocytosis-related prognostic signature for the prediction of prognosis and therapeutic response in gastric cancer.2024Genes & genomics
  50. SCYL1-mediated regulation of the mTORC1 signaling pathway inhibits autophagy and promotes gastric cancer metastasis.2024Journal of cancer research and clinical oncologyFree full text
  51. A novel tRNA-derived fragment tRF-17-18VBY9M works as a potential diagnostic biomarker for gastric cancer.2024Journal of cancer research and clinical oncologyFree full text
  52. Highly expressed B3GALT5-AS1 contributes to gastric cancer progression by recruiting WDR5 to mediate B3GALT5 and regulating β-catenin/ZEB1 axis.2024Journal of cellular and molecular medicineFree full text
  53. Clinical Effect of Tumor-Specific Total Nutrients in Patients with Adjuvant Chemotherapy After Radical Gastric Cancer Resection: A Randomized Controlled Trial.2024Journal of gastrointestinal cancerRCTFree full text
  54. Implementation of the Robocare nursing model for patients undergoing da Vinci robot-assisted radical gastrectomy for gastric cancer.2024Journal of robotic surgery
  55. ECHDC2 inhibits the proliferation of gastric cancer cells by binding with NEDD4 to degrade MCCC2 and reduce aerobic glycolysis.2024Molecular medicine (Cambridge, Mass.)Free full text
  56. High expression of TRIP13 is associated with tumor progression in H. pylori infection induced gastric cancer.2024Mutation research
  57. Long non-coding RNA AC010457.1 promotes the growth and EMT of gastric cancer via the PI3K/AKT axis.2024Pathology, research and practice
  58. CircBIRC6 facilitates the malignant progression via miR-488/GRIN2D-mediated CAV1-autophagy signal axis in gastric cancer.2024Pharmacological research
  59. Clinical features of upper gastrointestinal endoscopy in 3146 patients: a 9-year retrospective cohort study in Zanzibar Archipelago, Tanzania.2023African health sciencesFree full text
  60. Immunobiological signatures and the emerging role of SPP1 in predicting tumor heterogeneity, malignancy, and clinical outcomes in stomach adenocarcinoma.2023AgingFree full text
  61. The landscape of enhancer RNA identify prognosis-related molecular subtypes in gastric cancer.2023Cancer medicineFree full text
  62. Ubiquitin-specific peptidase 24 accelerates aerobic glycolysis and tumor progression in gastric carcinoma through stabilizing PLK1 to activate NOTCH1.2023Cancer scienceFree full text
  63. MicroRNA miR-1275 coordinately regulates AEA/LPA signals via targeting FAAH in lipid metabolism reprogramming of gastric cancer.2023Cell death & diseaseFree full text
  64. Overexpression of ferroptosis-related genes FSP1 and CISD1 is related to prognosis and tumor immune infiltration in gastric cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  65. Exosomal circ_0091741 promotes gastric cancer cell autophagy and chemoresistance via the miR-330-3p/TRIM14/Dvl2/Wnt/β-catenin axis.2023Human cell
  66. Hsa_circ_0001479 accelerates tumorigenesis of gastric cancer and mediates immune escape.2023International immunopharmacology
  67. Serum tRF-27-FDXXE6XRK45 as a Promising Biomarker for the Clinical Diagnosis in Gastric Cancer.2023International journal of medical sciencesFree full text
  68. Serum circular RNA hsa_circ_0000702 as a novel biomarker for diagnosis of gastric cancer.2023Journal of clinical laboratory analysisFree full text
  69. CHSY3 promotes proliferation and migration in gastric cancer and is associated with immune infiltration.2023Journal of translational medicineFree full text
  70. A comprehensive evaluation of serum tRF-29-R9J8909NF5JP as a novel diagnostic and prognostic biomarker for gastric cancer.2023Molecular carcinogenesis
  71. SLC7A11 promotes the progression of gastric cancer and regulates ferroptosis through PI3K/AKT pathway.2023Pathology, research and practice
  72. Gastric ectopic pancreas adenocarcinoma: A case report and literature review.2023Saudi medical journalFree full text
  73. Bacterial lipopolysaccharide related genes signature as potential biomarker for prognosis and immune treatment in gastric cancer.2023Scientific reportsFree full text
  74. High expression of GPR176 predicts poor prognosis of gastric cancer patients and promotes the proliferation, migration, and invasion of gastric cancer cells.2023Scientific reportsFree full text
  75. Dishevelled segment polarity protein 2 promotes gastric cancer progression through Wnt/β-catenin pathway.2023Tissue & cell
  76. Effect of bilateral paravertebral nerve block on cognitive function in elderly patients undergoing radical gastrectomy for gastric cancer: a prospective randomized double-blind controlled trial.2022BMC anesthesiologyRCTFree full text
  77. HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3.2022British journal of cancerFree full text
  78. NDUFS4 promotes tumor progression and predicts prognosis in gastric cancer.2022Carcinogenesis
  79. Kinase DYRK2 acts as a regulator of autophagy and an indicator of favorable prognosis in gastric carcinoma.2022Colloids and surfaces. B, Biointerfaces
  80. Outcomes of laparoscopic versus open total gastrectomy with D2 lymphadenectomy for gastric cancer: a systematic review and meta-analysis.2022European journal of medical researchFree full text
  81. Inhibition of Musashi-1 enhances chemotherapeutic sensitivity in gastric cancer patient-derived xenografts.2022Experimental biology and medicine (Maywood, N.J.)Free full text
  82. A Multi-Omics Study on the Effect of Helicobacter Pylori-Related Genes in the Tumor Immunity on Stomach Adenocarcinoma.2022Frontiers in cellular and infection microbiologyFree full text
  83. Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer.2022Frontiers in immunologyFree full text
  84. RUNX3-mediated circDYRK1A inhibits glutamine metabolism in gastric cancer by up-regulating microRNA-889-3p-dependent FBXO4.2022Journal of translational medicineFree full text
  85. Diagnostic Value of Circular RNA hsa_circ_0002874 Expression in Peripheral Blood of Patients with Gastric Cancer.2022Laboratory medicine
  86. Evaluation of serum tRF-23-Q99P9P9NDD as a potential biomarker for the clinical diagnosis of gastric cancer.2022Molecular medicine (Cambridge, Mass.)Free full text
  87. Immune-related gene TM4SF18 could promote the metastasis of gastric cancer cells and predict the prognosis of gastric cancer patients.2022Molecular oncologyFree full text
  88. Hsa_circ_0000437 promotes pathogenesis of gastric cancer and lymph node metastasis.2022Oncogene
  89. Block of Proliferation 1 Promotes Proliferation, Invasion and Epithelial Mesenchymal Transformation in Gastric Cancer.2022Oxidative medicine and cellular longevityFree full text
  90. Relationship between histological mixed-type early gastric cancer and lymph node metastasis: A systematic review and meta-analysis.2022PloS oneFree full text
  91. PRSS2 overexpression relates to poor prognosis and promotes proliferation, migration and invasion in gastric cancer.2022Tissue & cell
  92. ERCC6L promotes cell growth and metastasis in gastric cancer through activating NF-κB signaling.2021AgingFree full text
  93. Transcription factor PAX4 facilitates gastric cancer progression through interacting with miR-27b-3p/Grb2 axis.2021AgingFree full text
  94. MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling.2021AgingFree full text
  95. Clinicopathological features and lymph node metastasis risk in early gastric cancer with WHO criteria in China: 304 cases analysis.2021Annals of diagnostic pathology
  96. The correlation of microRNA-499 rs3746444 T>C locus with the susceptibility of gastric cancer: from a case-control study to a meta-analysis.2021Bioscience reportsFree full text
  97. GARP Correlates With Tumor-Infiltrating T-Cells and Predicts the Outcome of Gastric Cancer.2021Frontiers in immunologyFree full text
  98. Circulating serum exosomal miR-92a-3p as a novel biomarker for early diagnosis of gastric cancer.2021Future oncology (London, England)
  99. A commentary on "Updated evaluation of endoscopic submucosal dissection versus surgery for early gastric cancer: A systematic review and meta-analysis" [Int. J. Surg. 73 (2020) 28-41].2021International journal of surgery (London, England)
  100. GHR is involved in gastric cell growth and apoptosis via PI3K/AKT signalling.2021Journal of cellular and molecular medicineFree full text
  101. A systematic review of primary gastric diffuse large B-cell lymphoma: Clinical diagnosis, staging, treatment and prognostic factors.2021Leukemia research
  102. Diagnostic value of exosome derived long noncoding RNA in gastric cancer in Chinese population: A PRISMA-compliant systematic review and meta-analysis.2021MedicineFree full text
  103. SLC6A3 as a potential circulating biomarker for gastric cancer detection and progression monitoring.2021Pathology, research and practice
  104. MiR-216b regulates the tumorigenesis of gastric cancer by targeting PXN.2021Pathology, research and practice
  105. The effects of video based nursing education on perioperative anxiety and depression in patients with gastric cancer.2021Psychology, health & medicineRCT
  106. The Association Between Heavy Alcohol Use and Gastric Cancer.2021The American journal of gastroenterology
  107. Assessment of the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma based on pattern of post-surgical progression.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)7
  1. [Epidemiological characteristics of cancer mortality in the elderly in Qidong, 1972-2021].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. Transfer RNA-derived fragment tRF-23-Q99P9P9NDD promotes progression of gastric cancer by targeting ACADSB.2024Journal of Zhejiang University. Science. BFree full text
  3. [Tubular adenocarcinoma and signet ring cell carcinoma arising in gastric inverted hyperplastic polyp: report of a case].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Hsa_circ_0000670 promoted the progression of gastric cancer through the miR-515-5p/SIX1 molecular axis].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  5. [Long-term trend of gastric cancer survival rate in Qidong, 1972-2016].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  6. [Epidemic characteristics of stomach cancer mortality in Qidong during 1972-2016].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  7. [Expression of PTTG1 in gastric adenocarcinoma tissues and its relationship with prognosis].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status5
  1. Screening of Small Non-coding RNAs as an Auxiliary Diagnostic Biomarker for Gastric CancerEnrolling by invitationNCT06776835Lead sponsorStart 2023-12
  2. Laparoscopic Gastric Function Preserving Surgery Combined With Resection of the Anterior Lymphatic Drainage AreaStatus unknownNCT05160753Lead sponsorN/AStart 2022-01
  3. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  4. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  5. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 9 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 3320242025: 442025

3 hospitals in Nantong for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led9
  1. CoFe2O4-Based Multifunctional Nanozymes Remodel Tumor Redox Balance for Enhanced Osteosarcoma Treatment.2025International journal of nanomedicine
  2. Hybrid membranes-mediated biomimetic-nanoparticle carrying miR-665 for effective tumor treatment by remodeling tumor microenvironment.2025International journal of pharmaceutics
  3. PiRNA hsa_pir_018849 promotes the proliferation and invasion of osteosarcoma cells by regulating the stability of CCN5 mRNA.2025Journal of orthopaedic surgery and research
  4. The zinc finger protein560(ZNF560) functions as a novel oncogenic gene in osteosarcoma.2025Scientific reports
  5. Silencing FUT4 Inhibits the Progression of Osteosarcoma through Activation of FOXO1.2024Current pharmaceutical design
  6. TET3 Protein Represses Proliferation of the MG-63 Human Osteosarcoma Cell Line by Regulating DNA Demethylation: an Epigenetic Study.2024Folia biologica
  7. PDE1B, a potential biomarker associated with tumor microenvironment and clinical prognostic significance in osteosarcoma.2024Scientific reports
  8. Circular RNA circFOXP1 promotes angiogenesis by regulating microRNA -127-5p/CDKN2AIP signaling pathway in osteosarcoma.2021Bioengineered
  9. A natural product phillygenin suppresses osteosarcoma growth and metastasis by regulating the SHP-1/JAK2/STAT3 signaling.2021Bioscience, biotechnology, and biochemistry
Earlier papers (2016–2020)7
  1. PENK inhibits osteosarcoma cell migration by activating the PI3K/Akt signaling pathway.2020Journal of orthopaedic surgery and research
  2. MicroRNA-222 contributed to cell proliferation, invasion and migration via regulating YWHAG in osteosarcoma.2018European review for medical and pharmacological sciences
  3. miR-27a-3p promotes the malignant phenotypes of osteosarcoma by targeting ten-eleven translocation 1.2018International journal of oncology
  4. Downregulation of 14-3-3β inhibits proliferation and migration in osteosarcoma cells.2018Molecular medicine reports
  5. Downregulation of NKD1 in human osteosarcoma and its clinical significance.2018Molecular medicine reports
  6. Upregulation of HOXB7 promotes proliferation and metastasis of osteosarcoma cells.2017Molecular medicine reports
  7. CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma.2016International immunopharmacology

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 3 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Nantong for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 10 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
10
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 4420232024: 3320242025: 222025

1 hospital in Nantong for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led10
  1. ALDOC promotes neuroblastoma progression and modulates sensitivity to chemotherapy drugs by enhancing aerobic glycolysis.2025Frontiers in immunology
  2. Correlation of senescence-related gene FEN1 on neuroblastoma progression and cisplatin chemotherapy sensitivity.2025Oncology research
  3. LINC00894 inhibited neuron cellular apoptosis and regulated activating transcription factor 3 expression.2024Gene
  4. Radioprotective effect of Ginkgolide B on brain: the mediating role of DCC/MST1 signaling.2024International journal of radiation biology
  5. Homocysteine-potentiated Kelch-like ECH-associated protein 1 promotes senescence of neuroblastoma 2a cells via inhibiting ubiquitination of β-catenin.2024The European journal of neuroscience
  6. miR-6076 targets BCL6 in SH-SY5Y cells to regulate amyloid-β-induced neuronal damage.2023Journal of cellular and molecular medicine
  7. HIV-1 subtype B Tat enhances NOTCH3 signaling in astrocytes to mediate oxidative stress, inflammatory response, and neuronal apoptosis.2023Journal of neurovirology
  8. Disruption of the ADAM17/NF-κB feedback loop in astrocytes ameliorates HIV-1 Tat-induced inflammatory response and neuronal death.2023Journal of neurovirology
  9. TRAF4 Silencing Induces Cell Apoptosis and Improves Retinoic Acid Sensitivity in Human Neuroblastoma.2023Neurochemical research
  10. Dexmedetomidine inhibits cerebral nerve cell apoptosis after cerebral hemorrhage in rats via the Nrf2/HO-1/NQO1 signaling pathway.2022European review for medical and pharmacological sciences
Earlier papers (2016–2020)5
  1. MicroRNA-138 promotes neuroblastoma SH-SY5Y cell apoptosis by directly targeting DEK in Alzheimer's disease cell model.2020BMC neuroscience
  2. Protective Effect of Fucoidan against MPP+-Induced SH-SY5Y Cells Apoptosis by Affecting the PI3K/Akt Pathway.2020Marine drugs
  3. NLRP3 Inflammasome Activation Leads to Epileptic Neuronal Apoptosis.2018Current neurovascular research
  4. Silencing the ACAT1 Gene in Human SH-SY5Y Neuroblastoma Cells Inhibits the Expression of Cyclo-Oxygenase 2 (COX2) and Reduces β-Amyloid-Induced Toxicity Due to Activation of Protein Kinase C (PKC) and ERK.2018Medical science monitor : international medical journal of experimental and clinical research
  5. Down-regulation of C-terminal binding protein 2 (CtBP2) inhibits proliferation, migration, and invasion of human SHSY5Y cells in vitro.2017Neuroscience letters
All its trials on ClinicalTrials.gov, any status1
  1. Identification of New Gene Spliceosomes in NeuroblastomaStatus unknownNCT06502210Lead sponsorStart 2024-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 16 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.9%.

Papers led
16
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 3320232024: 1120242025: 552025

1 hospital in Nantong for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-11
    Registry
    NCT06246162

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Nantong UniversityNantong

  2. Recruiting
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07663253

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou

  3. Recruiting
    A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06497738

    Age 65 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesChangzhou, Nanjing, Nantong

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led16
  1. The Causal Relationship between Lipid Metabolites and Multiple Myeloma Risk: A Mendelian Randomization Study.2026Acta haematologica
  2. Effect of Bortezomib Treatment in Multiple Myeloma on Blood Coagulation Function, Renal Function, Immune Function, and the NF-κB Pathway-Associated Indicators.2025British journal of hospital medicine (London, England : 2005)
  3. Extracellular vesicle-mediated delivery of circp53 suppresses the progression of multiple cancers by activating the CypD/TRAP/HSP90 pathway.2025Experimental & molecular medicineFree full text
  4. NAT10 contributes to the progression of multiple myeloma through ac4C modification of GPR37.2025Hematology (Amsterdam, Netherlands)
  5. Downregulated expression of dual-specificity phosphatase-1 in multiple myeloma as a predictor of poor survival outcomes.2025Hematology (Amsterdam, Netherlands)
  6. Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma.2025Scientific reportsFree full text
  7. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling.2024Expert opinion on drug safety
  8. Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience.2023Annals of hematology
  9. RING box protein-1(RBX1), a key component of SCF E3 ligase, induced multiple myeloma cell drug-resistance though suppressing p27.2023Cancer biology & therapyFree full text
  10. YY1-induced LncRNA-TUG1 elevates YOD1 to promote cell proliferation and inhibit bortezomib sensitivity in multiple myeloma.2023Leukemia & lymphoma
  11. Significance of a tumor microenvironment-mediated P65-miR-30a-5p-BCL2L11 amplification loop in multiple myeloma.2022Experimental cell research
  12. The role of cystatin C in multiple myeloma.2022International journal of laboratory hematology
  13. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.2022Technology in cancer research & treatmentFree full text
  14. The Prognostic Role of Cyclin D1 in Multiple Myeloma: A Systematic Review and Meta-Analysis.2022Technology in cancer research & treatmentFree full text
  15. Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma.2021BioengineeredFree full text
  16. Decellularized ECM derived from normal bone involved in the viability and chemo-sensitivity in multiple myeloma cells.2021Experimental cell research
Chinese-language papers (not in the count)1
  1. [Expression and Clinical Significance of LINC00475 in Multiple Myeloma].2024Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status8
  1. Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple MyelomaRecruitingNCT06246162Lead sponsorPhase 1/Phase 2Start 2023-11
  2. The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma PatientsStatus unknownNCT05802992Lead sponsorPhase 3Start 2022-03
  3. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  4. A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple MyelomaRecruitingNCT06497738Study siteStart 2024-05
  5. SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary DiseaseCompletedNCT05900882Study sitePhase 2Start 2022-07
  6. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  7. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  8. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Nantong for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesThrombopoietin drugsImmunosuppressive treatment

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 3 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

1 hospital in Nantong for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesLymphoma & cancer-related HLHDiagnosis & prognosisTreatment regimens
Departments in papersMedical oncology
Papers it led3
  1. The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients.2024Annals of hematology
  2. Clinicopathological characteristics, prognostic factors, and outcomes of elderly patients with lymphoma-associated hemophagocytic lymphohistiocytosis: A multicenter analysis.2024Cancer medicineFree full text
  3. The Dosage Recommendation of Cyclosporin in Children with Hemophagocytic Lymphohistiocytosis based on Population Pharmacokinetic Model.2023Current pharmaceutical design
More papers found outside PubMed (not counted)6
  1. Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis2024Bloodconference-abstract
  2. Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients2024Bloodconference-abstract
  3. Clinical Significance of Serum High-Density Lipoprotein Cholesterol and Its Dynamic Change in Patients with Lymphoma-Associated Hemophagocytic Lymphohistiocytosis2023Bloodconference-abstract
  4. High Prevalence of MYD88 and CD79B Mutations and PD-L1 Alterations in Bone Marrow Large B Cell Lymphoma Associated with Hemophagocytic Lymphohistiocytosis2023Bloodconference-abstract
  5. Histiocytic Necrotizing Lymphadenitis with Hemophagocytic Lymphohistiocytosis: A Single-Center Analysis of Five Cases2023Bloodconference-abstract
  6. The Clinical Significance and Prognostic Value of Serum Beta-2 Microglobulin in Adult Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 326 Patients2023Bloodconference-abstract

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Nantong for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status3
  1. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06
  2. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  3. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Nantong for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Nantong for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 222025

1 hospital in Nantong for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 5 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.6%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025

1 hospital in Nantong for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

1 hospital in Nantong for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Nantong for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led1
  1. Identification of key necroptosis-related genes and immune landscape in patients with immunoglobulin A nephropathy.2024BMC nephrology
Earlier papers (2016–2020)1
  1. BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6/NF‑κB signaling pathway in glomerular mesangial cells.2020Molecular medicine reports
All its trials on ClinicalTrials.gov, any status3
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  2. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Nantong for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Nantong for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. A homozygous MITF mutation leads to familial Waardenburg syndrome type 4.2019American journal of medical genetics. Part A

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Nantong for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Nantong for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

南通大学附属医院

Affiliated Hospital of Nantong University

南通

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Nantong University; Affiliated Tumor Hospital of Nantong University; Second Affiliated Hospital of Nantong University; Nantong University Affiliated Hospital; Medical College of Nantong University; Affiliated Cancer Hospital of Nantong University; Taizhou People's Hospital Affiliated to Nantong University; Tumor Hospital Affiliated to Nantong University

Suggest a correctionDownload the data